Transform-HTN extension data to be presented at AHA
Mineralys Therapeutics flagged new long-term efficacy and safety findings from its Transform-HTN open-label extension trial of lorundrostat.
Results have not been presented yet; they are slated for a late-breaking session at American Heart Association Scientific Sessions 2026.
The update supports the drug’s sustained blood-pressure control profile in uncontrolled hypertension, with safety remaining consistent over longer treatment.
Presentation is scheduled for Nov. 8 in Chicago, positioning lorundrostat for higher visibility with clinicians and investors.
MLYS•
